App-Quantinova.ai

Conventionally fractionated radiation and anti-PD-L1 treatment to relieve radiation resistance via regulation proliferation pathway and immunity system.

Xiao Mei Gong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

The initial results for a phase III study of short-term radiotherapy plus chemotherapy vs long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR trial).

Jing Jin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

A prospective, multicenter, observational study of bevacizumab in combined with chemotherapy as first-line or second-line treatment in Chinese metastatic colorectal cancer.

Shukui Qin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Bevacizumab

Prognostic value of P53 for colorectal cancer after surgical resection of pulmonary metastases.

Cong Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Broad, hybrid capture-based next generation sequencing guided personalized therapy in metastatic colorectal cancer.

Helei Hou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

The meta analysis of pathological and long-term outcomes of laparoscopic vs. open surgery for rectal cancer.

Ke-Feng Ding - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Neoadjuvant chemotherapy with XELOX regimen for locally advanced operable colon cancer patients: a prospective phase II trial (NCT02415829).

Li Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).

Timothy Jay Price - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Prognostic and predictive inflammation-based markers for advanced colorectal cancer of the elderly patients.

Guifang Guo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Searching for predictive biomarkers on the efficacy of cetuximab plus chemotherapy for patients with unresectable colorectal liver-limited metastases: An expended biomarker analysis based on BELIEF study.

Jianmin Xu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Erbitux

Clostridium difficile carriage and its implications in preoperative colorectal cancer patients.

Yi Zheng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients treated with concurrent chemotherapy and intensity-modulated pelvic radiotherapy.

Xiang Bo Wan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Current risk stratification for colorectal cancer screening using a blood-based RNA test.

Choong-Chin Liew - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Inflammatory bowel disease

N/A

CEA clearance pattern as a predictor for pathologic complete response after neoadjuvant chemoradiation for rectal cancer: Results of the FOWARC trial.

Huabin Hu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Adrucil injection

Worse prognosis in young female patients with non-metastatic colorectal cancer: A hospital-based analysis of 5,295 patients in China.

Ji Zhu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Efficacy and dosimetry of 125I radioactive seed implantation for locally recurrent rectal cancer.

Hao Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Accuracy of ultrasound in the diagnosis of cervical lymph node metastasis in esophageal cancer: A meta-analysis.

Xue-Feng Leng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

N/A

Identifying targetable genetic alterations in advanced gastric cancer through broad, hybrid capture-based next generation sequencing.

Dong Liu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Impact of skeletal muscle loss after adjuvant chemoradiotherapy in patients with gastric cancer.

Yan Gao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Survival benefit of neoadjuvant versus adjuvant radiotherapy in lymph node positive esophageal cancer patients undergoing curative resection.

Nishitha Thumallapally - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

N/A

Filters

24782 Abstracts